<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT942-16325</title>
	</head>
	<body>
		<main>
			<p>940411 FT  11 APR 94 / UK Company News: Medeva agreement Medeva, the pharmaceuticals company, has signed an exclusive agreement to market Wellcome's new hay fever treatment, Semprex-D, in the US. Adams Laboratories, Medeva's US subsidiary which has a 220-strong sales force specialising in respiratory products, will start marketing Semprex-D this month on behalf of Wellcome's US arm, Burroughs Wellcome.</p>
		</main>
</body></html>
            